Consequently, the high carrier frequency has enabled GPV-specific breast cancer risks to be estimated for these specific variants, recognizing that this approach is not possible for most CHEK2 GPVs due to the limited sample size of individuals with specific GPVs. Here, CHEK2 is linked to breast cancer.